BriaCell (BCTX) Therapeutics announces the addition of UCLA Health Jonsson Comprehensive Cancer Center to its ongoing pivotal Phase 3 clinical study evaluating Bria-IMT in combination with a checkpoint inhibitor versus physician’s choice in patients with advanced metastatic breast cancer, MBC. “The inclusion of UCLA Health underscores our strategy to partner with top-tier institutions to accelerate trial enrollment and execution,” said Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer. “We remain confident in our timeline for sharing top-line data in 2026.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCTX:
- BriaCell Secures New Zealand Patent for Cancer Immunotherapy
- BriaCell awarded New Zealand patent for its whole cell technology
- BriaCell’s BriaPro Files Patent for Innovative Cancer Treatment Platform
- BriaCell subsidiary BriaPro files patent application for TILsRx
- BriaCell to Present Key Clinical Data at ESMO 2025